Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Del D Miller

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Psychiatric Services (Washington, D.C.)|July 28, 2006
Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trialMiranda H Chakos, Ira D Glick, Alexander L Miller, et al.
Psychiatric Services (Washington, D.C.)|July 28, 2006
Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE studyMarvin S Swartz, H Ryan Wagner, Jeffrey W Swanson, et al.
Schizophrenia Research|September 21, 2005
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trialDel D Miller, Joseph P McEvoy, Sonia M Davis, et al.
Psychiatric Services (Washington, D.C.)|August 2, 2016
Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention StudyPeter F Buckley, Nina R Schooler, Donald C Goff, et al.
Schizophrenia Research|January 15, 2008
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE studyMarvin S Swartz, H Ryan Wagner, Jeffrey W Swanson, et al.
The Journal of Nervous and Mental Disease|March 15, 2006
Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE studyMarvin S Swartz, H Ryan Wagner, Jeffrey W Swanson, et al.
The British Journal of Psychiatry : the Journal of Mental Science|October 2, 2008
Extrapyramidal side-effects of antipsychotics in a randomised trialDel D Miller, Stanley N Caroff, Sonia M Davis, et al.
Schizophrenia Bulletin|May 30, 2014
Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE studyPeter F Buckley, Nina R Schooler, Donald C Goff, et al.
Schizophrenia Research|January 12, 2023
Longitudinal study of inflammation and relapse in schizophreniaBrian J Miller, Henrique Lemos, Nina R Schooler, et al.
Schizophrenia Research|July 24, 2017
Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?Anilkumar Pillai, Nina R Schooler, Diya Peter, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Psychiatric Services (Washington, D.C.)|July 28, 2006
Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trialMiranda H Chakos, Ira D Glick, Alexander L Miller, et al.
Psychiatric Services (Washington, D.C.)|July 28, 2006
Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE studyMarvin S Swartz, H Ryan Wagner, Jeffrey W Swanson, et al.
Schizophrenia Research|September 21, 2005
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trialDel D Miller, Joseph P McEvoy, Sonia M Davis, et al.
Psychiatric Services (Washington, D.C.)|August 2, 2016
Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention StudyPeter F Buckley, Nina R Schooler, Donald C Goff, et al.
Schizophrenia Research|January 15, 2008
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE studyMarvin S Swartz, H Ryan Wagner, Jeffrey W Swanson, et al.
The Journal of Nervous and Mental Disease|March 15, 2006
Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE studyMarvin S Swartz, H Ryan Wagner, Jeffrey W Swanson, et al.
The British Journal of Psychiatry : the Journal of Mental Science|October 2, 2008
Extrapyramidal side-effects of antipsychotics in a randomised trialDel D Miller, Stanley N Caroff, Sonia M Davis, et al.
Schizophrenia Bulletin|May 30, 2014
Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE studyPeter F Buckley, Nina R Schooler, Donald C Goff, et al.
Schizophrenia Research|January 12, 2023
Longitudinal study of inflammation and relapse in schizophreniaBrian J Miller, Henrique Lemos, Nina R Schooler, et al.
Schizophrenia Research|July 24, 2017
Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?Anilkumar Pillai, Nina R Schooler, Diya Peter, et al.
Pageof 4